GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

151.7B

Vuru Grade

75.00/100

Current Price

$100.58
-0.01 (-0.01%)

Growth Price

$26.98
Overvalued by 73.18%

Stability Price

$15.14
Overvalued by 84.94%

Company Metrics

  • 17.92 P/E
  • 7.33 P/S
  • 11.2 P/B
  • 5.613 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 15.55M Avg. Vol.
  • 1.69B Shares
  • 151.7B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Gilead Sciences, Inc. (GILD) Buys FDA Priority Voucher
Bidness ETC - 19 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) announced November 19 that it paid $125 billion to the small Canadian company, Knight Therapeutics Inc. (CVE:GUD) in exchange for its FDA priority review voucher.
Gilead Sciences Earns “A+” Credit Rating (GILD) - sleekmoney
Shining on Major News: Gilead Sciences (NASDAQ:GILD), Lowe's Companies ... - Gaining Green
Why You Shouldn't Worry About Gilead Sciences, Inc.
Motley Fool - Oct 30, 2014
It shouldn't be too shocking to learn that sales of Gilead Sciences' (NASDAQ: GILD ) mega blockbuster Sovaldi sagged in the third quarter.
Gilead Sciences: Even More Attractive After Third Quarter Results (GILD) - Seeking Alpha (registration)
Most Active Weekly Options: Gilead Sciences, Inc. (GILD) - Schaeffers Research (blog)
2 More Gilead Sciences, Inc. Blockbusters You Ought to Know About
Motley Fool - Nov 3, 2014
Gilead Sciences (NASDAQ: GILD ) hepatitis C drugs may be capturing all the attention, but its Gilead's HIV drug franchise that's been responsible for the company's long-standing success. Gilead is racking up billions in global revenue thanks to a slate ...
Is This Trend Making Gilead Sciences, Inc. Worry?
Motley Fool - Nov 5, 2014
If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead's (NASDAQ: GILD ) Harvoni, you expect that your insurer will pay for it. But that isn't happening in all ...
Gilead: Stay The Course (GILD) - Seeking Alpha (registration)
Trade of the Day: Gilead Sciences Stock on Sale
Investorplace.com - Nov 18, 2014
Gilead Sciences, Inc. (GILD) - I last reviewed this stock on Oct. 28, at $113.25, but it has been featured as the Trade of the Day numerous times over the past two years.
Dispelling Some Of The Myths Surrounding Gilead Sciences - Seeking Alpha (registration)
European Commission Grants Marketing Authorization for Gilead's Harvoni ... - MarketWatch
Gilead Sciences In Correction Mode
Benzinga - Nov 13, 2014
Gilead Sciences, Inc. (NASDAQ: GILD) had been on a rocket ship ride up until September, rising from the $60s to over $100 since April.
Sealed Air Corp (SEE), Louisiana-Pacific Corporation (LPX), Gilead Sciences ... - Tech Insider
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape - Nasdaq
Gilead Sciences (GILD) Stock Falls On Rumors Of Icahn's Stake In The Company
Bidness ETC - Nov 21, 2014
Gilead Sciences, Inc. (NASDAQ:GILD) stock fell 1.71% during trading yesterday, as 20.03 million shares changed hands, up from the 30-day average trading volume of 16.5 million.
Traders Buy Gilead Sciences on Weakness (GILD) - sleekmoney
Laggard Stocks - Gilead Sciences, Inc. (NASDAQ:GILD), Staples, Inc. (NASDAQ ... - Techsonian (press release)
How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple ...
Motley Fool - Oct 26, 2014
Gilead Sciences (NASDAQ: GILD ) recently got its hepatitis C drug Harvoni approved by the Food and Drug Administration and announced that it would cost $94,500, substantially more than the $84,000 that wholesalers pay for Sovaldi, one of the two ...
Gilead Sciences' (GILD) Harvoni Continues Winning Streak With Green Light ...
Bidness ETC - Nov 19, 2014
Gilead Sciences, Inc.'s (NASDAQ:GILD) hepatitis C drug Harvoni has received the European Commission's marketing authorization, the company announced yesterday.
Gilead's Value Without Its Hep C Franchise
Seeking Alpha (registration) - Nov 18, 2014
Admittedly analyzing Gilead Sciences without accounting for the Hep C business borders on the absurd. This is consistent, however, with how absurdly the market is discounting Gilead's stock, primarily due to ... several pending NDA filings before year ...